中文名稱:化合物A 779(3TFA) | 英文名稱:A 779 |
CAS:159432-28-7 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
產(chǎn)品類別: 抑制劑 | |
貨號: T7616 |
Name | A 779 |
Description | A 779 is a potent antagonist of the G-protein-coupled receptor Mas, the Ang1-7 receptor, which is distinct from conventional AngII. |
Cell Research | HUVECs were cultured in vitro and divided into six groups:?the control group (normal medium), the ox-LDL group(treated with 75 mg/L ox-LDL), the ox-LDL+ Ang-(1-7) group (1 μmol/L Ang-(1-7) pretreated for 30 minutes, then intervened with 75 mg/L ox-LDL), the ox-LDL+ Ang-(1-7)+ A-779 group(1 μmol/L A-779 (Mas receptor) pretreated for 30 minutes, 1 μmol/L Ang-(1-7) pretreated for 30 minutes, then intervened with 75 mg/L ox-LDL), the ox-LDL+ A-779 group (1 μmol/L A-779 pretreated for 30 minutes, then intervened with 75 mg/L ox-LDL),?the ox-LDL+ HTA125 group (10 μg/L HTA125 (TLR4-blocking antibody) pretreated for 30 minutes, then intervened with 75 mg/L ox-LDL ).?The corresponding index was detected after 24 hours after intervention.?Apoptosis of cells were detected by Annexin V-FITC/PI double staining flow cytometry and transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL).?The generation of reactive oxygen species (ROS), products in oxidative stress, were detected by DCFH-DA staining.?The mRNA and protein expression levels of NADPH oxidase 4(NOX4) and TLR4 were detected by real-time reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting analysis respectively[1]. |
In vitro | A 779抑制了由Ang II上調(diào)的增殖細胞核抗原(PCNA)蛋白表達,但A 779單獨使用并不誘導(dǎo)VSMCs的增殖和遷移。預(yù)處理Ang-(1-7)顯著延緩了Ang II誘導(dǎo)的VSMCs炎癥反應(yīng),這一反應(yīng)與MCP-1、VCAM-1和IL-1β的表達上調(diào)有關(guān),而Ang-(1-7)的這種效果被A 779阻斷。但A 779單獨使用并不誘發(fā)VSMCs的炎癥反應(yīng)[1]。 |
In vivo | A 779通過抑制Ang1-7級聯(lián)反應(yīng),顯著消除了卡托普利對骨代謝、礦化和微觀結(jié)構(gòu)保護作用。此外,A 779還恢復(fù)了卵巢切除(OVX)對RANKL表達的影響,以及對ACE-1/AngII/AT1R級聯(lián)反應(yīng)的影響,下調(diào)了OPG表達和ACE-2/Ang1-7/Mas途徑。與臨床觀察到的繼ACE-1抑制后骨保護特性一致,ACE-2/Ang1-7/Mas信號的局部激活和骨吸收的抑制似乎是卡托普利骨保護效應(yīng)的責(zé)任機制,這可能為治療殘疾性骨骼和骨骼肌疾病提供潛在的治療價值。 |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : 50 mg/mL (57.28 mM), Sonication is recommended. |
Keywords | Inhibitor | A 779 | inhibit | A-779 | Angiotensin Receptor | A779 |
Inhibitors Related | Sacubitril/Valsartan | Losartan | Captopril | Tranilast | Irbesartan | Enalapril Maleate |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP2年
|
上海鴻肽生物科技有限公司
|
2024-12-17 | |
¥1341 |
VIP14年
|
湖南匯百侍生物科技有限公司
|
2024-12-12 | |
¥417 |
VIP1年
|
TargetMol中國(陶術(shù)生物)
|
2024-12-02 | |
¥297.00 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 | |
詢價 |
VIP1年
|
寶雞締都醫(yī)藥化工有限公司
|
2024-11-25 | |
詢價 |
VIP2年
|
上海拓旸生物科技有限公司
|
2024-08-26 |